Process parameter development for the scaled generation of stem cell-derived pancreatic endocrine cells

Area of Science:

• Biotechnology
• Regenerative Medicine
• Endocrinology

Background:

• Diabetes mellitus, characterized by hyperglycemia, affects millions globally, with Type 1 diabetes accounting for 10% of cases.
• Islet transplantation is effective but limited by donor islet scarcity.
• Pluripotent stem cells present an unlimited source for generating insulin-producing cells, offering a potential alternative therapy.

Purpose of the Study:

• To explore the potential of stem cell-derived pancreatic progenitors and mature insulin-producing cells for diabetes treatment.
• To highlight the necessity of scalable manufacturing for clinical relevance.
• To identify critical process parameters and strategies for optimizing bioprocesses.

Main Methods:

• Review of advances in differentiation protocols for stem cell-derived pancreatic endocrine cells.
• Discussion of strategies for bioprocess parameter optimization.
• Identification of critical quality attributes influencing cell manufacturing.

Main Results:

• Significant progress has been made in differentiation protocols, showing efficacy in animal models and potential for clinical trials.
• Scalable manufacturing is essential for translating stem cell therapies into widespread clinical use.
• Optimization of bioprocess parameters is key to ensuring the quality and therapeutic potential of stem cell-derived cells.

Conclusions:

• Stem cell-derived pancreatic cells, including progenitors and mature insulin-producing cells, hold significant promise for treating type 1 diabetes.
• Addressing challenges in scalable manufacturing through rigorous bioprocess optimization is critical for clinical translation.
• Further research into critical process parameters will facilitate the development of robust manufacturing strategies for human pluripotent stem cell-derived pancreatic endocrine cells.